Aptamer Group Partners with Pharmahungary on Heart and Muscle Delivery Vehicles
Aptamer Group has agreed a research collaboration with Pharmahungary to build Optimer targeting vehicles for heart and skeletal muscle cells, carrying Pharmahungary's therapeutic microRNA. Costs are shared, with Pharmahungary funding the preclinical programme, and Aptamer will hold a 50% stake in the combined therapeutic. The aim is preclinical data to support joint licensing deals.